These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. News in multiple sclerosis: Remyelination as a therapeutic target. Matías-Guiu J; Gomez-Pinedo U; Matias-Guiu JA Med Clin (Barc); 2017 Apr; 148(8):377-380. PubMed ID: 27923464 [No Abstract] [Full Text] [Related]
24. Targeted delivery of glucocorticoids to macrophages in a mouse model of multiple sclerosis using inorganic-organic hybrid nanoparticles. Montes-Cobos E; Ring S; Fischer HJ; Heck J; Strauß J; Schwaninger M; Reichardt SD; Feldmann C; Lühder F; Reichardt HM J Control Release; 2017 Jan; 245():157-169. PubMed ID: 27919626 [TBL] [Abstract][Full Text] [Related]
25. Association between exposure to farm animals and pets and risk of Multiple Sclerosis. Siejka D; Taylor B; Ponsonby AL; Dwyer T; van der Mei I Mult Scler Relat Disord; 2016 Nov; 10():53-56. PubMed ID: 27919498 [TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497 [TBL] [Abstract][Full Text] [Related]
27. Brain MRI atrophy quantification in MS: From methods to clinical application. Rocca MA; Battaglini M; Benedict RH; De Stefano N; Geurts JJ; Henry RG; Horsfield MA; Jenkinson M; Pagani E; Filippi M Neurology; 2017 Jan; 88(4):403-413. PubMed ID: 27986875 [TBL] [Abstract][Full Text] [Related]
28. Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry. Prosperini L; de Rossi N; Scarpazza C; Moiola L; Cosottini M; Gerevini S; Capra R; PLoS One; 2016; 11(12):e0168376. PubMed ID: 27997580 [TBL] [Abstract][Full Text] [Related]
29. Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis. Ziemssen T; Ashtamker N; Rubinchick S; Knappertz V; Comi G Expert Opin Drug Saf; 2017 Feb; 16(2):247-255. PubMed ID: 27989217 [TBL] [Abstract][Full Text] [Related]
30. The association of cognitive impairment with gray matter atrophy and cortical lesion load in clinically isolated syndrome. Diker S; Has AC; Kurne A; Göçmen R; Oğuz KK; Karabudak R Mult Scler Relat Disord; 2016 Nov; 10():14-21. PubMed ID: 27919482 [TBL] [Abstract][Full Text] [Related]
31. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Olsson T; Barcellos LF; Alfredsson L Nat Rev Neurol; 2017 Jan; 13(1):25-36. PubMed ID: 27934854 [TBL] [Abstract][Full Text] [Related]
32. Affective disorders and Health-Related Quality of Life (HRQoL) in adolescents and young adults with Multiple Sclerosis (MS): the moderating role of resilience. Rainone N; Chiodi A; Lanzillo R; Magri V; Napolitano A; Morra VB; Valerio P; Freda MF Qual Life Res; 2017 Mar; 26(3):727-736. PubMed ID: 27928696 [TBL] [Abstract][Full Text] [Related]
33. Persian adaptation of a questionnaire of environmental risk factors in multiple sclerosis (EnvIMS-Q). Sahraian MA; Naghshineh H; Shati M; Jahromi SR; Rezaei N Mult Scler Relat Disord; 2016 Nov; 10():82-85. PubMed ID: 27919505 [TBL] [Abstract][Full Text] [Related]
34. Quality of life and its correlates in adolescent multiple sclerosis patients. Ostojic S; Stevanovic D; Jancic J Mult Scler Relat Disord; 2016 Nov; 10():57-62. PubMed ID: 27919499 [TBL] [Abstract][Full Text] [Related]
35. Attitudes to cannabis and patterns of use among Canadians with multiple sclerosis. Banwell E; Pavisian B; Lee L; Feinstein A Mult Scler Relat Disord; 2016 Nov; 10():123-126. PubMed ID: 27919478 [TBL] [Abstract][Full Text] [Related]
36. Natalizumab treatment of multiple sclerosis: new insights. Delbue S; Comar M; Ferrante P Immunotherapy; 2017 Jan; 9(2):157-171. PubMed ID: 28004598 [TBL] [Abstract][Full Text] [Related]